Exclude Patient Type Detail Header
No
Footnote
<sup>9</sup> Acceptable sx control may require trials of multiple tx options [CP]. Persist w/ new tx for adequate trial to determine efficacy, tolerability; d/c tx if efficacy not demonstrated. Assemble combo tx methodically, adding new tx only when relative efficacy of preceding tx known [EO]. Appropriate duration: 8-12 wks for behavioral, 4-8 wks for pharmacologic tx.<br><br>
<sup>10</sup> Behavior tx (1st-line) [S/B] includes bladder training, bladder control strategies, PFMT, fluid mgmt. Behavioral tx may be combined w/ drug tx [C], including antimuscarinics or β3-adrenoceptor agonists (mirabegron). If inadequate sx control and/or unacceptable ADE w/ 1 antimuscarinic: manage constipation/dry mouth, modify dose, or try a different antimuscarinic or a β3-adrenoceptor agonist (mirabegron) [CP]. Before abandoning effective antimuscarinic tx: manage constipation, dry mouth, including bowel and fluid mgmt, dose modification or alternative antimuscarinic. [CP] If IR and ER formulations available, ER preferred d/t lower rates of dry mouth. [S/B]
<br><br>
<sup>11</sup> If failure and/or ADE w/ 1 med: try at least 1 other med prior to considering 3rd-line tx.
<sup>10</sup> Behavior tx (1st-line) [S/B] includes bladder training, bladder control strategies, PFMT, fluid mgmt. Behavioral tx may be combined w/ drug tx [C], including antimuscarinics or β3-adrenoceptor agonists (mirabegron). If inadequate sx control and/or unacceptable ADE w/ 1 antimuscarinic: manage constipation/dry mouth, modify dose, or try a different antimuscarinic or a β3-adrenoceptor agonist (mirabegron) [CP]. Before abandoning effective antimuscarinic tx: manage constipation, dry mouth, including bowel and fluid mgmt, dose modification or alternative antimuscarinic. [CP] If IR and ER formulations available, ER preferred d/t lower rates of dry mouth. [S/B]
<br><br>
<sup>11</sup> If failure and/or ADE w/ 1 med: try at least 1 other med prior to considering 3rd-line tx.
Detail Type
Text